Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $51.21.

Several brokerages have recently issued reports on KYMR. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research report on Monday, August 26th. Guggenheim raised their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Oppenheimer raised their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Finally, Morgan Stanley lifted their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $41.96 on Friday. Kymera Therapeutics has a fifty-two week low of $16.94 and a fifty-two week high of $53.27. The stock’s 50-day moving average is $47.17 and its two-hundred day moving average is $41.62. The firm has a market cap of $2.72 billion, a P/E ratio of -17.93 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s revenue was down 20.9% compared to the same quarter last year. During the same period last year, the business posted ($0.90) earnings per share. On average, equities analysts expect that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in Kymera Therapeutics by 7.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after purchasing an additional 308,954 shares during the last quarter. Quarry LP bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $95,000. HighTower Advisors LLC bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $494,000. HighVista Strategies LLC bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $603,000. Finally, Cinctive Capital Management LP bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $2,688,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.